REFERENCES
- Howlader N, Noone A, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. (eds.). SEER Cancer Statistics Review, 1975–2012. Bethesda, MD: National Cancer Institute, Available at http://seer.cancer.gov/csr/1975_2012/.
- Scheffer G, Wijngaard P, Flens M, Izquierdo M, Slovak M, Pinedo H, et al. The drug resistance-related protein LRP is the major human vault protein. Nat Med 1995;1:578–582.
- Izquierdo M, Shoemaker R, Flens M, Scheffer G, Wu L, Prather T, et al. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int J Cancer 1996;65:230–238.
- Izquierdo M, van der Zee A, Vermorken J, van der Valk P, Belien J, Giaccone G, et al. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 1995;87:1230–1237.
- List A, Spier C, Grogan T, Johnson C, Roe D, Greer J, et al. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 1996;87:2464–2469.
- Kitazono M, Sumizawa T, Takebayashi Y, Chen Z, Furukawa T, Nagayama S, et al. Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst 1999;91:1647–1645.
- Dalton W, Scheper R. Lung resistance-related protein: determining its role in multidrug resistance. J Natl Cancer Inst 1999;91:1604–1600.
- Scheffer G, Schroeijers A, Izquierdo M, Wiemer E, Scheper R. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 2000;12:550–556.
- Pohl G, Filipits M, Suchomel R, Stranzl T, Depisch D, Pirker R. Expression of the lung resistance protein (LRP) in primary breast cancer. Anticancer Res 1999;19:5051–5055.
- Wood N, Streckfus C, Dai X. Salivary multidrug resistance proteins in breast cancer therapeutics. J Dent Res 2004;83(A): 69.
- Sugawara I, Akiyama S, Scheper R, Itoyama S. Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP. Cancer Letters 1997;112: 23–31.
- Staging for carcinoma of the breast. In AJCC Cancer Staging Manual, 5th edition, ID Fleming, JS Cooper, DE Henson, et al. (eds.). Philadelphia: J.B. Lippincott-Raven, 1998, 171–180.
- Streckfus C, Bigler L, Dellinger T, Kuhn M, Chouinard N, Dai X. The expression of the c-erbB-2 receptor protein in glandular salivary secretions. J Oral Path Med 2004;33: 595–600.
- Streckfus C, Bigler L, Dellinger T, Dai X, Kingman A, Thigpen JT. The presence of c-erbB-2, and CA 15-3 in saliva and serum among women with breast carcinoma: a preliminary study. Clin Cancer Res 2000;6(6):2363–2370.
- Chugani D, Rome L, Kedersha N. Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex. J Cell Sci 1993;106:23–29.
- Abbondanza C, Rossi V, Roscigno A, Gallo L, Belsito A, Piluso G, et al. Interaction of vault particles with estrogen receptor in the MCF-7 breast cancer cells. J Cell Biol 1998;141:1301–1310.
- Beato M. Gene regulation by steroid hormones. Cell 1989;56:335–344.
- Marshall E. Search for a killer. Focus shifts from fat to hormones. Science 1993;259:618–621.
- Streckfus C, Bigler L, Edwards C, Guajardo-Streckfus C, Bigler S. Using saliva secretions to model disease Progression. In Salivary Diagnostics, CF Streckfus (ed.). Heidelberg: Springer Press, 2015, 187–198.
- Pant S, Hilton H, Burczynski M. The multifaceted exosome: Biogenesis, role in normal and aberrant cellular function, and frontiers for pharmacological and biomarker opportunities. Biochemical Pharmacol 2012;83:1484–1495.